Want to see IDXG full AI Analyst Report?
Interpace Diagnostics Group (IDXG) AI Stock Analysis
Interpace Diagnostics Group
(Other OTC:IDXG)
Robust financial recovery and compelling valuation are primary strengths driving the score; weak technical momentum partially offsets gains while corporate actions support future upside potential.
Interpace Diagnostics Group (IDXG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $33.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,794
- Price to Earnings (P/E)
- 0.2
- Beta (1Y)
- 1.93
- Revenue Growth
- -20.48%
- EPS Growth
- 537.47%
- Country
- US
- Employees
- 102
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Interpace Diagnostics Group Business Overview & Revenue Model
Company Description
Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its key offerings is PancraGEN, a comprehensive genomic...
How the Company Makes Money
IDXG makes money primarily by providing clinical diagnostic testing services and collecting reimbursement for those tests. The core revenue model is fee-for-service: physicians (and other healthcare providers) order the company’s tests for appropriat...
Interpace Diagnostics Group Financial Statement Overview
Summary
Strong turnaround to high profitability with 63%+ margins, positive equity turnaround to $23M, and solid cash flow generation despite recent revenue declines.
Income Statement
85Very PositiveBalance Sheet
90Very PositiveCash Flow
82Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.14M | 38.73M | 46.93M | 40.21M | 31.84M | 41.31M |
| Gross Profit | 23.04M | 24.13M | 29.93M | 23.90M | 18.23M | 17.95M |
| EBITDA | 4.83M | 4.76M | 8.36M | 4.41M | -2.27M | -1.33M |
| Net Income | 24.45M | 24.57M | 6.70M | 802.00K | -5.87M | -14.75M |
Balance Sheet | ||||||
| Total Assets | 34.55M | 33.84M | 14.79M | 13.02M | 15.98M | 38.43M |
| Cash, Cash Equivalents and Short-Term Investments | 2.69M | 2.50M | 1.46M | 3.50M | 4.83M | 3.31M |
| Total Debt | 974.00K | 1.18M | 5.86M | 11.19M | 16.09M | 10.72M |
| Total Liabilities | 11.30M | 11.47M | 17.01M | 28.16M | 79.05M | 80.84M |
| Stockholders Equity | 23.24M | 22.36M | -2.22M | -15.14M | -63.07M | -42.42M |
Cash Flow | ||||||
| Free Cash Flow | 4.10M | 5.47M | 3.77M | 3.32M | -8.01M | -9.07M |
| Operating Cash Flow | 4.46M | 5.83M | 4.65M | 3.79M | -7.69M | -8.72M |
| Investing Cash Flow | -353.00K | -356.00K | -876.00K | -87.00K | 6.21M | -315.00K |
| Financing Cash Flow | -1.92M | -4.43M | -5.81M | -5.03M | 3.00M | 8.98M |
Interpace Diagnostics Group Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDXG, the sentiment is Negative. The current price of 5.59 is below the 20-day moving average (MA) of 5.67, below the 50-day MA of 6.33, and below the 200-day MA of 8.18, indicating a bearish trend. The MACD of -0.25 indicates Negative momentum. The RSI at 47.16 is Neutral, neither overbought nor oversold. The STOCH value of 30.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IDXG.
Interpace Diagnostics Group Risk Analysis
Interpace Diagnostics Group disclosed 63 risk factors in its most recent earnings report. Interpace Diagnostics Group reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksInterpace Diagnostics Group Peers Comparison
Overall Rating
VCYT78Outperform- IDXG75Outperform
CSTL70Outperform
GH55Neutral
NEO54Neutral
MYGN53Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| VCYT | 78Outperform | $4.02B | 34.73 | 8.64% | ― | 17.28% | 323.64% |
| IDXG | 75Outperform | $33.01M | 0.21 | 142.98% | ― | -20.48% | 537.47% |
| CSTL | 70Outperform | $1.14B | -56.34 | -4.15% | ― | 3.18% | -100.37% |
| GH | 55Neutral | $23.99B | -51.23 | 211.46% | ― | 42.74% | -4.60% |
| NEO | 54Neutral | $2.25B | -70.42 | -3.97% | ― | 11.08% | 71.76% |
| MYGN | 53Neutral | $607.38M | -5.32 | -32.59% | ― | -3.16% | 72.02% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IDXG | Interpace Diagnostics Group Inc. | 5.59 | 0.59 | 11.84% | |
| MYGN | Myriad Genetics | 6.35 | -0.11 | -1.70% | |
| VCYT | Veracyte Inc | 50.01 | 13.89 | 38.46% | |
| NEO | NeoGenomics Inc. | 17.38 | 7.28 | 72.08% | |
| GH | Guardant Health | 178.80 | 80.66 | 82.19% | |
| CSTL | Castle Biosciences | 37.16 | 5.53 | 17.48% |
Interpace Diagnostics Group Corporate Events
Interpace Diagnostics Executes Reverse Split to Support Nasdaq Uplisting
PositiveAt the August 20, 2026 annual meeting, Interpace Biosciences’ stockholders approved giving the board discretion to implement a reverse stock split between 1-for-2 and 1-for-10, and the board subsequently set the ratio at 1-for-5. Following the...
Interpace Diagnostics Shareholders Approve Governance and Equity Plans
PositiveAt its August 20, 2026 annual meeting, Interpace Diagnostics Group shareholders approved an amended and restated certificate of incorporation and granted the board authority to implement a reverse stock split within a one-for-two to one-for-ten range...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 27, 2026